Anaplastic Throid Carcinoma
Conditions
Brief summary
The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
Interventions
DRUGNKG2D CAR-NK with PD-1 Antibody
Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.
Sponsors
Zhejiang Provincial People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-75 years (including boundary values), male or female. 2. Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm. 3. Liver and kidney function is good, and can tolerate treatment. 4. Be able to cooperate with the completion of treatment and follow-up work. 5. No other systemic diseases, including other malignancies.
Exclusion criteria
1. Need to breastfeed the baby or have fertility needs； 2. Immune system diseases; 3. Diseases of the blood system; 4. Mental system diseases; 5. Interstitial pneumonia, lung disease, etc.; 6. Failure to follow rules of this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability | From the start of the trial to day 56 after the first infusion of CAR-NK. | Safety and tolerability at 28 days after combination therapy, dose limiting toxicity (DLT) and maximum tolerated dose (MTD) were determined. |
Countries
China
Contacts
Primary ContactMinghua Ge
Outcome results
None listed